Evangelist Franklin Graham prayed on a sidewalk outside the Pentagon Thursday after his invitation to a prayer service inside was withdrawn because of comments that insulted people of other religions.
To prevent diseases, including human papillomavirus (HPV)-associated cancers, pertussis, and meningococcal disease, routine immunization of adolescents aged 11–12 years is recommended by the Advisory Committee on Immunization Practices.
NIS-Teen methodology, including methods for weighting and synthesizing provider-reported vaccination histories, has been described separately (ftp://gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NIS/NISTEENPUF14_DUG.pdf).
A revised adequate provider data definition was implemented in 2014 and retrospectively applied to 2013 NIS-Teen data for purposes of comparability (
The Advisory Committee on Immunization Practices (ACIP) recommends that adolescents aged 11–12 years routinely receive vaccines to prevent diseases, including human papillomavirus (HPV)-associated cancers, pertussis, and meningococcal disease (1).
To assess vaccination coverage among adolescents in the United States, CDC analyzed data collected regarding 21,875 adolescents through the 2015 National Immunization Survey-Teen (NIS-Teen).* During 2014–2015, coverage among adolescents aged 13–17 years increased for each HPV vaccine dose among males, including ≥1 HPV vaccine dose (from 41.7% to 49.8%), and increased modestly for ≥1 HPV vaccine dose among females (from 60.0% to 62.8%) and ≥1 quadrivalent meningococcal conjugate vaccine (Men ACWY) dose (from 79.3% to 81.3%).
HPV vaccination coverage (≥1, ≥2, or ≥3 doses) increased in 28 states/local areas among males and in seven states among females.During 2006–2014, national coverage with ≥1 dose of tetanus-diphtheria-acellular pertussis vaccine (Tdap) and ≥1 dose of quadrivalent meningococcal conjugate vaccine (Men ACWY) increased annually.Since 2007, among females, HPV vaccination coverage has lagged behind Tdap and Men ACWY coverage, with gaps of 28 and 17 percentage points, respectively, in 2014.During 2014–2015, among males, coverage with each HPV vaccine dose increased, with percentage point increases of 8.1 for ≥1 dose, 7.6 for ≥2 doses, and 6.5 for ≥3 doses.Among females, coverage with ≥1 HPV vaccine dose increased modestly (2.8 percentage points).Despite limited progress, HPV vaccination coverage remained lower than Men ACWY and tetanus, diphtheria, and acellular pertussis vaccine (Tdap) coverage, indicating continued missed opportunities for HPV-associated cancer prevention.NIS-Teen monitors vaccination coverage among adolescents aged 13–17 years in the 50 states, District of Columbia (DC), selected local areas, and territories Through telephone interviews with adolescents’ parents/guardians, information is collected on adolescent, maternal, and household sociodemographic characteristics and vaccination providers.In 2015, ≥1-dose HPV vaccination coverage among females aged 13 years was lower than coverage among females aged ≥15 years, but was similar among males in all age groups (Table 1).Although HPV vaccination coverage remained higher among females than among males, the percentage point difference in coverage estimates decreased over time (Figure 1).This suggests that HPV vaccine is not being routinely administered at visits when other recommended vaccines are given, and demonstrates ongoing missed opportunities for the prevention of HPV-associated outcomes, including cancers.Routine age-appropriate administration of all recommended vaccines to adolescents aged 11–12 years, and strong, consistent recommendations by clinicians are important to maintaining high vaccination coverage for Tdap and Men ACWY vaccines and improving HPV vaccination coverage.